您的位置:PharmaNews 研发动态 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe(2)
本文章共2117字,分2页,当前第2页,快速翻页:

http://www.sec.gov/. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
 

Source: Bionovo, Inc.

CONTACT: Tom Chesterman, +1-510-601-2000, investor@bionovo.com; or
Investors, Joe Diaz, Robert Blum or Joe Dorame, all of Lytham Partners, LLC,
+1-602-889-9700, bnvi@lythampartners.com, for Bionovo, Inc.
 

Web Site: http://www.bionovo.com/
 

转载自pharmaLive


 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

  deCODE Shows how Genetic Risk of Kidney

  New pathway to Parkinson's and Alzheimer

  Plant Compound Resveratrol Shown to Supp

  WaferGen Announces Purchase of SmartChip

  Researchers Solve Mystery of Uner Tan Sy

  Shionogi Inc. Announces FDA Approval of

  Abraxis BioScience and Specialised Thera

  Abbott's Simcor ( niacin extended-releas

  FDA Approves Drug for Chronic Drooling i

  Quintiles Announces New European Headqua

Geron to Proceed with First Human Clinic

Orexigen Therapeutics Announces Publicat

Basilea Pharmaceutica AG (CH) - Data on

Study Results Show That Oral Contracepti

勃林格殷格翰糖尿病药物linagliptin一项Ⅲ期

厄洛替尼在欧盟提交申请用于具EGFR 活化突变

诺华公司肾癌治疗药物依维莫司新适应证研究

罗氏发布在研糖尿病药taspoglutide的Ⅲ期临

罗氏正式提交赫赛汀第二代共轭化合物曲妥珠

达沙替尼申请用于慢性髓性白血病一线治疗

相关评论

    
本文章所属分类:首页 研发动态